Clonal hematopoiesis of indeterminate potential (CHIP) is a known risk factor for coronary artery disease, though its precise role in disease progression continues to emerge. This study leverages ...
DurAVR ® THV delivered a favorable hemodynamic profile sustained to one-year, with an EOA of 2.1 + 0.2 cm 2 and a mean pressure gradient (MPG) of 8.6 + 2.6 mmHg. At one-year, clinical safety outcomes ...
MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart compa ...
A number of inquests concerning people who died from undiagnosed aortic dissections at Nottingham University Hospitals have ...
Anteris or the Company ) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart ...
SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis. After adjustments, patients on SGLT2 inhibitors had a significantly reduced risk of progression to severe ...
School of Chemistry, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K. School of Chemistry, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K ...
The DapaTAVI trial previously showed reduced rates of death or worsening heart failure with dapagliflozin in older adults with aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback